Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG
Anne Zaremba(National Center for Tumor Diseases), Lisa Zimmer(The University of Sydney), Jochen Utikal(German Cancer Research Center), Edgar Dippel(Klinikum Ludwigshafen), Rudolf Herbst(Helios Klinikum Erfurt), Klaus Griewank(Düsseldorf University Hospital), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Christoffer Gebhardt(Universität Hamburg), Michael Weichenthal(Christian-Albrechts-Universität zu Kiel), Claudia Pföhler(Saarland University), Sebastian Haferkamp(University Hospital Regensburg), Andrea Forschner(University of Tübingen), Dirk Schadendorf(National Center for Tumor Diseases), Friedegund Meier(National Center for Tumor Diseases), Sophia Kreft(Charité - Universitätsmedizin Berlin), Lucie Heinzerling(LMU Klinikum), Julia Welzel(University Hospital Augsburg), Elisabeth Livingstone(German Cancer Research Center), Selma Ugurel(Klinikum Bielefeld), Frank Meiß(University of Freiburg), Anca Sindrilaru(Universität Ulm), Ulrike Leiter(University of Tübingen), Martin Kaatz(SRH Wald-Klinikum Gera), H. Löffler(University of Mannheim), Michael Sachse(Klinikum Bremerhaven-Reinkenheide), Peter Mohr(Elbe Kliniken Stade-Buxtehude), Carsten Weishaupt(University Hospital Münster), Jens Ulrich, Patrick Terheyden(University Hospital Schleswig-Holstein)
Cited by 13
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k